<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">LUP</journal-id>
<journal-id journal-id-type="hwp">splup</journal-id>
<journal-id journal-id-type="nlm-ta">Lupus</journal-id>
<journal-title>Lupus</journal-title>
<issn pub-type="ppub">0961-2033</issn>
<issn pub-type="epub">1477-0962</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage UK: London, England</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/0961203313479419</article-id>
<article-id pub-id-type="publisher-id">10.1177_0961203313479419</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Pediatric lupus</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Urinary neutrophil gelatinase-associated lipocalin as a marker of severe lupus nephritis in children</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Hammad</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313479419">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Mosaad</surname><given-names>Y</given-names></name>
<xref ref-type="aff" rid="aff2-0961203313479419">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Elhanbly</surname><given-names>S</given-names></name>
<xref ref-type="aff" rid="aff3-0961203313479419">3</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Youssef</surname><given-names>H</given-names></name>
<xref ref-type="aff" rid="aff4-0961203313479419">4</xref>
<xref ref-type="corresp" rid="corresp1-0961203313479419"/>
</contrib>
<contrib contrib-type="author">
<name><surname>Refaaey</surname><given-names>A El</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313479419">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Elhusseini</surname><given-names>F</given-names></name>
<xref ref-type="aff" rid="aff5-0961203313479419">5</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Bakr</surname><given-names>A</given-names></name>
<xref ref-type="aff" rid="aff1-0961203313479419">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-0961203313479419"><label>1</label>Pediatric Nephrology Unit, Mansoura University Children's Hospital, Egypt</aff>
<aff id="aff2-0961203313479419"><label>2</label>Clinical Immunology Unit, Clinical Pathology Department, Mansoura Faculty of Medicine, Egypt</aff>
<aff id="aff3-0961203313479419"><label>3</label>Dermatology and Andrology Department, Mansoura Faculty of Medicine, Egypt</aff>
<aff id="aff4-0961203313479419"><label>4</label>Department of Rheumatology, Aberdeen Royal Infirmary, UK</aff>
<aff id="aff5-0961203313479419"><label>5</label>Department of Pathology, Mansoura Faculty of Medicine, Mansoura University, Egypt</aff>
<author-notes>
<corresp id="corresp1-0961203313479419">Hazem Youssef, Department of Rheumatology, Aberdeen Royal Infirmary, Aberdeen AB25 2ZN, UK. Email: <email>hazemyoussef@nhs.net</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>4</month>
<year>2013</year>
</pub-date>
<volume>22</volume>
<issue>5</issue>
<fpage>486</fpage>
<lpage>491</lpage>
<history>
<date date-type="received"><day>4</day><month>8</month><year>2012</year></date>
<date date-type="accepted"><day>21</day><month>1</month><year>2013</year></date>
</history>
<permissions>
<copyright-statement>© The Author(s), 2013. Reprints and permissions: http://www.sagepub.co.uk/journalsPermissions.nav</copyright-statement>
<copyright-year>2013</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<sec id="sec8-0961203313479419"><title>Introduction</title>
<p>More than 60% of children with systemic lupus erythematosus (SLE) develop lupus nephritis (LN). Neutrophil gelatinase-associated lipocalin (NGAL) is a protein secreted by leukocytes during inflammation and is overexpressed in the kidneys following ischemic and nephrotoxic damage.</p>
</sec>
<sec id="sec9-0961203313479419"><title>Aim</title>
<p>To study urinary and serum NGAL in children with SLE and investigate their possible role as markers of renal involvement.</p>
</sec>
<sec id="sec10-0961203313479419"><title>Methods</title>
<p>Urinary and serum levels of NGAL were assessed in 33 children with active SLE (22 with and 11 without LN) and compared to 15 matched controls.</p>
</sec>
<sec id="sec11-0961203313479419"><title>Results</title>
<p>Children with SLE had elevated urinary NGAL as compared to controls (<italic>P</italic> &lt; 0.001). Levels of urinary NGAL were higher in patients with LN than those without LN (<italic>P</italic> &lt; 0.001). In patients with LN, serum levels of NGAL were not significantly different from controls (<italic>P</italic> = 0.4) and urinary NGAL correlated with the renal score of the Systemic Lupus Erythematosus Disease Activity Index (<italic>r</italic> = 0.5, <italic>P</italic> = 0.02) but not with serum NGAL (<italic>P</italic> = 0.5). Urinary NGAL was significantly predictive of class III and IV LN (<italic>P</italic> = 0.005) with 91% sensitivity and 70% specificity to levels ≥10.07 ng/mg creatinine.</p>
</sec>
<sec id="sec12-0961203313479419"><title>Conclusions</title>
<p>Urinary NGAL is a sensitive marker of proliferative nephritis in juvenile SLE.</p>
</sec>
</abstract>
<kwd-group>
<kwd>Urinary NGAL</kwd>
<kwd>lipocalin 2</kwd>
<kwd>proliferative lupus nephritis</kwd>
<kwd>juvenile SLE</kwd>
<kwd>renal lupus</kwd>
<kwd>systemic lupus erythematosus</kwd>
<kwd>nephritis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="sec1-0961203313479419" sec-type="intro"><title>Introduction</title>
<p>Renal involvement in patients with systemic lupus erythematosus (SLE) leads to a significant morbidity and mortality.<sup><xref ref-type="bibr" rid="bibr1-0961203313479419">1</xref></sup> Renal disease is more common in children than adults with SLE<sup><xref ref-type="bibr" rid="bibr2-0961203313479419">2</xref></sup> with 60–80% of children with lupus having some form of renal involvement during the course of their disease.<sup><xref ref-type="bibr" rid="bibr3-0961203313479419">3</xref></sup></p>
<p>Neutrophil gelatinase-associated lipocalin (NGAL; lipocalin-2) is a 25-kd protein secreted by leukocytes in different conditions including infections and neoplasia<sup><xref ref-type="bibr" rid="bibr4-0961203313479419">4</xref>,<xref ref-type="bibr" rid="bibr5-0961203313479419">5</xref></sup> and is considered to be a biomarker of renal injury in various conditions.<sup><xref ref-type="bibr" rid="bibr6-0961203313479419">6</xref><xref ref-type="bibr" rid="bibr7-0961203313479419"/>–<xref ref-type="bibr" rid="bibr8-0961203313479419">8</xref></sup> In animals, NGAL is highly expressed in the kidney after ischemic or nephrotoxic injury<sup><xref ref-type="bibr" rid="bibr9-0961203313479419">9</xref>,<xref ref-type="bibr" rid="bibr10-0961203313479419">10</xref></sup> and similar findings have been reported in humans.<sup><xref ref-type="bibr" rid="bibr11-0961203313479419">11</xref><xref ref-type="bibr" rid="bibr12-0961203313479419"/>–<xref ref-type="bibr" rid="bibr13-0961203313479419">13</xref></sup></p>
<p>The aim of this work is to assess the levels of urinary and serum NGAL in children with lupus and investigate their possible role as markers of renal involvement.</p>
<sec id="sec2-0961203313479419" sec-type="methods"><title>Patients and methods</title>
<p>This cross-sectional study included 33 children with active SLE, 25 females and eight males with an age range of 5 to 16 years (median (interquartile range, IQR) 10 (8–12) years) recruited consecutively before immune suppression from the Pediatric Nephrology Unit and Pediatric Rheumatology Clinic, Mansoura University Children's Hospital and Dermatology Clinic, Mansoura University Hospital, Egypt. Patients were diagnosed according to the modified criteria of the American College of Rheumatology for the classification of SLE.<sup><xref ref-type="bibr" rid="bibr14-0961203313479419">14</xref></sup> Children with urinary tract infection (&gt;100,000 colony-forming units in urine culture) were excluded from the study. A group of 15 healthy children matched for age and sex were recruited as controls. Informed consent was obtained from the parents of all children participating in the study and the local ethics committee approved the research protocol.</p>
<p>Eighteen patients (54%) had inflammatory arthritis, two (6%) had thrombocytopenia, six patients (18.2%) had anemia, six (18.2%) had alopecia, two (6%) had Raynaud's phenomena, seven (21.2%) had oral ulcers, three (9%) had vasculitic rash and four patients (12.1%) had CNS involvement. All patients had normal serum creatinine levels. Patients were divided into two groups according to the presence (lupus nephritis (LN) group) or absence of abnormal urinary sediment and other manifestations of renal involvement. Twenty two patients (18 females and four males) had evidence of LN. The remaining 11 patients (seven females and four males) had no evidence of renal involvement. Disease activity was assessed using the Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).<sup><xref ref-type="bibr" rid="bibr15-0961203313479419">15</xref></sup> Renal involvement was assessed using the renal SLEDAI (R-SLEDAI), which includes four renal elements of the SLEDAI score, namely proteinuria, hematuria, pyuria and urinary casts. Each item in the R-SLEDAI is scored between 0 and 4 points. Thus, the total R-SLEDAI score ranges from 0 to 16. Children with renal involvement were subjected to renal biopsies for histopathologic classification using the International Society of Nephrology/Renal Pathology Society (ISN/RPS) classification system.<sup><xref ref-type="bibr" rid="bibr16-0961203313479419">16</xref></sup> Accordingly, among the 22 children with LN one had class I, nine had class II, four had class III and eight children had class IV LN.</p>
<p>Urine and serum samples were concomitantly obtained from all patients immediately after diagnosis before any immunosuppressive medications were administered. In children with LN, renal biopsy was done either on the same day or within a maximum of 48 hours after urine and blood sampling. Serum was assessed for NGAL without further manipulation, while first morning urine samples were centrifuged at 3,000 revolutions per minute for 10 minutes to remove debris. Human NGAL was measured using the quantitative sandwich immunoassay technique (Quantikine, R&amp;D systems, Minneapolis, USA). A monoclonal antibody specific for NGAL was pre-coated onto a microplate. Standards and samples were pipetted into the wells and NGAL was bound by the immobilized antibody. After washing away any unbound substances, an enzyme-linked monoclonal antibody specific for NGAL was added to the wells. Following a wash to remove any unbound antibody-enzyme reagent, a substrate solution was added to the wells and the color developed in proportion to the amount of NGAL bound in the initial step. The color development was then stopped and the intensity of the color measured. Serum values ranged from 4 to 177 ng/ml and urine values ranged from 0.4 to 72 ng/ml.</p>
</sec>
<sec id="sec3-0961203313479419"><title>Statistical methods</title>
<p>Data was analyzed by SPSS (Statistical Package for Social Sciences) under Windows (version 17). Data was non-parametric according to the Kolmogorov Smirnov test. Data was expressed as median and IQR. Tests used included the Mann-Whitney test and the Spearman correlation test. To compare the sensitivity and specificity of urinary NGAL for detection of the histopathologic proliferative forms of renal affection, receiver-operator characteristic (ROC) was used. <italic>P</italic> &lt; 0.05 was considered significant.</p>
</sec>
</sec>
<sec id="sec4-0961203313479419" sec-type="results"><title>Results</title>
<p>Children with SLE had elevated urinary NGAL levels as compared to controls (median (IQR) = 22.3 (14.5–32.4) vs 9.8 (9.7–12.1) ng/ml, respectively; <italic>P</italic> &lt; 0.001) (<xref ref-type="fig" rid="fig1-0961203313479419">Figure 1</xref>). Levels of urinary NGAL were corrected to the levels of urinary creatinine. Corrected levels of NGAL were significantly higher in the LN group compared to non-LN patients (median (IQR) = 13 (10.25–18.75) vs 5.6 (0.95–7.45) ng/mg creatinine, respectively; <italic>P</italic> &lt; 0.001). Serum levels of NGAL were not significantly different between children with LN and controls (median (IQR) = 96.7 (95.6–126.5) vs 112 (100.8–134.4) ng/ml, respectively; <italic>P</italic> = 0.4). There was no significant relationship between urinary NGAL and total SLEDAI score (<italic>r</italic> = 0.32, <italic>P</italic> = 0.064). In children with LN however, there were significant positive correlations between urinary NGAL and R-SLEDAI (<italic>r</italic> = 0.5, <italic>P</italic> = 0.02) (<xref ref-type="fig" rid="fig2-0961203313479419">Figure 2</xref>) as well as the titers of anti-double stranded DNA (anti-ds DNA) (<italic>r</italic> = 0.5, <italic>P</italic> = 0.01) and negative correlation with serum complement C3 levels (<italic>r</italic> = −0.55, <italic>P</italic> = 0.007). There was no significant correlation between urinary and serum levels of NGAL (<italic>r</italic> = 0.09; <italic>P</italic> = 0.5) (<xref ref-type="table" rid="table1-0961203313479419">Table 1</xref>).
<fig id="fig1-0961203313479419" position="float"><label>Figure 1</label><caption><p>Comparison of urinary NGAL levels in patients and controls.</p>
<p>NGAL: neutrophil gelatinase-associated lipocalin.</p></caption><graphic xlink:href="10.1177_0961203313479419-fig1.tif"/>
</fig>
<fig id="fig2-0961203313479419" position="float"><label>Figure 2</label><caption><p>Correlation between urinary NGAL (lipocalin 2) and R-SLEDAI in the LN group.</p>
<p>LN: lupus nephritis; NGAL: neutrophil gelatinase-associated lipocalin; R-SLEDAI: Renal Systemic Lupus Erythematosus Disease Activity Index.</p></caption><graphic xlink:href="10.1177_0961203313479419-fig2.tif"/>
</fig>
<table-wrap id="table1-0961203313479419" position="float"><label>Table 1</label><caption><p>Correlation between urinary NGAL and laboratory parameters</p></caption>
<graphic alternate-form-of="table1-0961203313479419" xlink:href="10.1177_0961203313479419-table1.tif"/>
<table frame="hsides"><thead align="left">
<tr><th>r<xref ref-type="table-fn" rid="table-fn1-0961203313479419">*</xref></th>
<th>P</th>
</tr></thead>
<tbody align="left">
<tr>
<td>Proteinuria</td>
<td>0.3</td>
<td>0.1</td>
</tr>
<tr>
<td>c.Cr.Cl</td>
<td>0.11</td>
<td>0.2</td>
</tr>
<tr>
<td>C3</td>
<td>−0.55</td>
<td>0.007</td>
</tr>
<tr>
<td>Anti-ds DNA</td>
<td>0.5</td>
<td>0.01</td>
</tr>
<tr>
<td>ANA</td>
<td>−0.25</td>
<td>0.14</td>
</tr>
<tr>
<td>Platelet count</td>
<td>0.2</td>
<td>0.32</td>
</tr>
<tr>
<td>Serum NGAL</td>
<td>0.09</td>
<td>0.5</td>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-0961203313479419"><label>*</label><p>Spearman's correlation coefficient.</p></fn>
<fn id="table-fn2-0961203313479419"><p>ANA: anti-nuclear antibody; c.Cr.Cl: corrected creatinine clearance; C3: complement 3; Anti-ds DNA: anti-double stranded deoxyribonucleic acid; NGAL: neutrophil gelatinase-associated lipocalin.</p></fn></table-wrap-foot>
</table-wrap></p>
<p>Levels of urinary NGAL were statistically significant in the detection of class III and IV LN (<italic>P</italic> = 0.005). In our cohort, a cutoff point of 10.07  ng/mg creatinine was noted in class III and IV with a sensitivity of 91% and specificity of 70% (<xref ref-type="fig" rid="fig3-0961203313479419">Figure 3</xref>).
<fig id="fig3-0961203313479419" position="float"><label>Figure 3</label><caption><p>ROC curve of sensitivity and specificity of urinary NGAL for detection of proliferative LN.</p>
<p>LN: lupus nephritis; NGAL: neutrophil gelatinase-associated lipocalin.</p></caption><graphic xlink:href="10.1177_0961203313479419-fig3.tif"/>
</fig></p>
</sec>
<sec id="sec5-0961203313479419" sec-type="discussion"><title>Discussion</title>
<p>SLE is an autoimmune disease characterized by the presence of autoantibodies including anti-ds DNA antibodies.<sup><xref ref-type="bibr" rid="bibr14-0961203313479419">14</xref></sup> In the present study, only urinary and not serum NGAL levels were significantly higher in children with SLE in comparison to controls. Moreover, urinary NGAL was significantly higher in children with LN than those without. In patients with LN, levels of urinary NGAL correlated with R-SLEDAI, C3 and anti-ds DNA titers but not with total SLEDAI or serum NGAL levels. Increased urinary NGAL in our patients is mostly due to increased production by the kidneys rather than simple excretion from the circulation as serum levels were not elevated in comparison to controls. This is supported by the finding that urinary NGAL levels were not correlated with corrected creatinine clearance (c.Cr.Cl). In addition, increased urinary NGAL is not due to systemic disease activity because their levels were not correlated with SLEDAI or serum NGAL levels. Also, increased urinary NGAL is not a simple epiphenomenon of increased urinary protein excretion because urinary NGAL levels were not correlated with the degree of proteinuria in patients with LN. This is also supported by the finding that in patients with LN, urinary NGAL correlated significantly with levels of anti-ds DNA and C3, both known indicators of renal involvement in lupus.<sup><xref ref-type="bibr" rid="bibr17-0961203313479419">17</xref><xref ref-type="bibr" rid="bibr18-0961203313479419"/>–<xref ref-type="bibr" rid="bibr19-0961203313479419">19</xref></sup> This was also confirmed by the significant positive correlation between urinary NGAL and renal scores of SLEDAI. A pathogenic role for anti-ds DNA antibodies in the development of LN has been suggested by various authors.<sup><xref ref-type="bibr" rid="bibr20-0961203313479419">20</xref><xref ref-type="bibr" rid="bibr21-0961203313479419"/>–<xref ref-type="bibr" rid="bibr22-0961203313479419">22</xref></sup> Experimentally, it is reported that anti-ds DNA monoclonal antibodies can increase the expression of NGAL in the kidney when administered both in vitro and in vivo.<sup><xref ref-type="bibr" rid="bibr23-0961203313479419">23</xref></sup> There is a general agreement that increased urinary NGAL in LN is due to increased intrarenal production rather than simple urinary over filtration from extra renal sources.<sup><xref ref-type="bibr" rid="bibr24-0961203313479419">24</xref>,</sup> <sup><xref ref-type="bibr" rid="bibr25-0961203313479419">25</xref></sup> The poor correlation between urinary and serum levels of NGAL in the current work confirms the conclusions of previous studies that extra renal sources of NGAL are not responsible for increased urinary levels in LN. The exact intrarenal source of increased urinary NGAL in LN is still unclear. Because urinary NGAL is considered a sensitive marker in acute ischemic kidney injury,<sup><xref ref-type="bibr" rid="bibr26-0961203313479419">26</xref></sup> increased urinary NGAL in childhood onset LN was initially hypothesized to be due to overexpression in injured tubular cells.<sup><xref ref-type="bibr" rid="bibr24-0961203313479419">24</xref></sup> However, other renal sources have also been suggested including increased loss of protein by glomeruli and overproduction by mesangial or glomerular epithelial cells.<sup><xref ref-type="bibr" rid="bibr27-0961203313479419">27</xref></sup></p>
<p>Urinary NGAL has been studied by various authors both in children and adults with SLE. However, most of these studies focused on the ability of NGAL to monitor for the presence of nephritis or predict the occurrence of renal flares in biopsy-proven LN patients. Rubinstein et al. reported that elevated urinary NGAL was a better marker than anti-ds DNA antibodies to predict incoming renal flares in adult lupus patients with a history of previous nephritis and they found a drop in NGAL levels with onset of flares.<sup><xref ref-type="bibr" rid="bibr28-0961203313479419">28</xref></sup> In children with SLE, urinary levels of NGAL were markedly elevated at the time of renal flares compared to their levels 3 months earlier.<sup><xref ref-type="bibr" rid="bibr25-0961203313479419">25</xref></sup> On the other hand, Kiani et al. found that urinary vascular cell adhesion molecule -1 (VCAM-1) levels but not NGAL levels were correlated with renal activity in SLE.<sup><xref ref-type="bibr" rid="bibr29-0961203313479419">29</xref></sup> To our knowledge, until now only limited data existed about the link between NGAL and renal histopathology in LN. Although Brunner et al. have found that levels of urinary NGAL (&gt;0.6 ng/mg urinary creatinine) are predictive of juvenile SLE with biopsy-proven nephritis, they did not compare its level in children with proliferative forms (class III and IV) or those with other forms (class II and V).<sup><xref ref-type="bibr" rid="bibr24-0961203313479419">24</xref></sup> Similarly, in adult lupus the significance for urinary NGAL as a predictor of LN was reported but again without testing its potential to predict proliferative forms.<sup><xref ref-type="bibr" rid="bibr30-0961203313479419">30</xref></sup> In clinical practice a renal biopsy is often required for the assessment of the degree of renal involvement in lupus. Although generally considered a safe procedure, renal biopsy has potential risks.<sup><xref ref-type="bibr" rid="bibr31-0961203313479419">31</xref></sup> Also, LN is frequently focal and therefore large tissue samples may be required for accurate assessment of the extent of glomerular involvement.<sup><xref ref-type="bibr" rid="bibr32-0961203313479419">32</xref></sup> Proliferative forms of LN (class III and IV) require aggressive therapy.<sup><xref ref-type="bibr" rid="bibr33-0961203313479419">33</xref></sup> It is very important therefore to have a reliable biomarker of severe renal involvement in SLE. In the current work urinary levels of NGAL were statistically significant in differentiation between proliferative and milder forms of LN. Urinary NGAL levels (≥10.07 ng/mg creatinine) were predictive of proliferative LN with a sensitivity of 91% and specificity of 70%. Our results are in agreement with the findings in experimental crescentic LN animal models in which NGAL was overexpressed in the glomeruli and its urinary levels were persistently elevated for 9 weeks after induction of the disease.<sup><xref ref-type="bibr" rid="bibr34-0961203313479419">34</xref></sup> It is well known that crescents are not found in class I or II but may be a component of class III and IV.<sup><xref ref-type="bibr" rid="bibr16-0961203313479419">16</xref></sup> In humans, Suzuki et al. found increased urinary NGAL levels in seven children with class IV LN in comparison to five children with class V LN.<sup><xref ref-type="bibr" rid="bibr25-0961203313479419">25</xref></sup> On the other hand, a recent study by Brunner et al. on 76 adults and children with SLE did not find any relationship between urinary NGAL levels and any of the histological features including cellular crescents of active renal inflammation. Interestingly, however, when they re-analyzed their data of a subset of patients in whom urine samples were taken no later than the day of the renal biopsy, urinary NGAL levels were significantly lower in patients with cellular crescents compared to those without.<sup><xref ref-type="bibr" rid="bibr35-0961203313479419">35</xref></sup> The differences between our results and the previous study may be due to the fact that children ≤18 years old constituted only 34% of the patients in the Brunner et al. cohort. Differences in the behavior and response of urinary NGAL in pediatric compared to adult lupus have been hypothesized.<sup><xref ref-type="bibr" rid="bibr28-0961203313479419">28</xref></sup> Moreover, our study only included newly diagnosed, treatment-naive patients in whom no immunosuppressive therapy was used to affect renal histopathology or urinary NGAL levels. In addition, in the study of Brunner et al. urinary biomarkers including NGAL were studied in relation to separate histological features reflecting either activity or chronicity of nephritis but not in relation to categorized histopathologic classes as is the case in our study.</p>
<p>There are points of strength for the current work. First, urinary NGAL sampling was performed within a few days of renal biopsies thus increasing its suitability to be used as a predictor of histopathologic findings in the studied cohort. Second, the study was conducted on active patients diagnosed for the first time before the use of any immunosuppressive medications including steroids that can affect the histopathology and/or activity of renal disease and also before the use of cyclophosphamide that can cause uroepithelial injury with subsequent effects on urinary NGAL levels. The limitations of the current work, however, lie with the fact that this is a single center study on a relatively small number of patients so the results are preliminary and further studies on large number of patients including those presenting with abnormal renal function are recommended. Moreover, this is a cross-sectional study with no follow-up data on post-treatment levels of NGAL to assess its clinical utility as a predictor of therapeutic response.</p>
<p>We conclude that urinary NGAL is not only a marker of renal involvement but can also be used as a predictor of proliferative forms of LN in children with newly diagnosed lupus.</p>
</sec>
</body>
<back>
<sec id="sec6-0961203313479419"><title>Funding</title>
<p>This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.</p>
</sec>
<sec id="sec7-0961203313479419"><title>Conflict of Interest Statement</title>
<p>The authors have no conflicts of interest to declare.</p>
</sec>
<ref-list>
<title>References</title>
<ref id="bibr1-0961203313479419"><label>1</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Korbet</surname><given-names>SM</given-names></name><name><surname>Lewis</surname><given-names>EJ</given-names></name><name><surname>Schwartz</surname><given-names>MM</given-names></name><name><surname>Reichlin</surname><given-names>M</given-names></name><name><surname>Evans</surname><given-names>J</given-names></name><name><surname>Rohde</surname><given-names>RD</given-names></name></person-group>. <article-title>Factors predictive of outcome in severe lupus nephritis. Lupus Nephritis Collaborative Study Group</article-title>. <source>Am J Kidney Dis</source> <year>2000</year>; <volume>35</volume>: <fpage>904</fpage>–<lpage>914</lpage>.</citation></ref>
<ref id="bibr2-0961203313479419"><label>2</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Perfumo</surname><given-names>F</given-names></name><name><surname>Martini</surname><given-names>A</given-names></name></person-group>. <article-title>Lupus nephritis in children</article-title>. <source>Lupus</source> <year>2005</year>; <volume>14</volume>: <fpage>83</fpage>–<lpage>88</lpage>.</citation></ref>
<ref id="bibr3-0961203313479419"><label>3</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gloor</surname><given-names>JM</given-names></name></person-group>. <article-title>Lupus nephritis in children</article-title>. <source>Lupus</source> <year>1998</year>; <volume>7</volume>: <fpage>639</fpage>–<lpage>643</lpage>.</citation></ref>
<ref id="bibr4-0961203313479419"><label>4</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>SY</given-names></name><name><surname>Pauksen</surname><given-names>K</given-names></name><name><surname>Venge</surname><given-names>P</given-names></name></person-group>. <article-title>Serum measurements of human neutrophil lipocalin (HNL) discriminate between acute bacterial and viral infections</article-title>. <source>Scand J Clin Lab Invest</source> <year>1995</year>; <volume>55</volume>: <fpage>125</fpage>–<lpage>131</lpage>.</citation></ref>
<ref id="bibr5-0961203313479419"><label>5</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nielsen</surname><given-names>BS</given-names></name><name><surname>Borregaard</surname><given-names>N</given-names></name><name><surname>Bundgaard</surname><given-names>JR</given-names></name><name><surname>Timshel</surname><given-names>S</given-names></name><name><surname>Sehested</surname><given-names>M</given-names></name><name><surname>Kjeldsen</surname><given-names>L</given-names></name></person-group>. <article-title>Induction of NGAL synthesis in epithelial cells of human colorectal neoplasia and inflammatory bowel diseases</article-title>. <source>Gut</source> <year>1996</year>; <volume>38</volume>: <fpage>414</fpage>–<lpage>420</lpage>.</citation></ref>
<ref id="bibr6-0961203313479419"><label>6</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Prada</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury</article-title>. <source>J Am Soc Nephrol</source> <year>2003</year>; <volume>14</volume>: <fpage>2534</fpage>–<lpage>2543</lpage>.</citation></ref>
<ref id="bibr7-0961203313479419"><label>7</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Mori</surname><given-names>K</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><name><surname>Barasch</surname><given-names>J</given-names></name><name><surname>Devarajan</surname><given-names>P</given-names></name></person-group>. <article-title>Neutrophil gelatinase-associated lipocalin: A novel early urinary biomarker for cisplatin nephrotoxicity</article-title>. <source>Am J Nephrol</source> <year>2004</year>; <volume>24</volume>: <fpage>307</fpage>–<lpage>315</lpage>.</citation></ref>
<ref id="bibr8-0961203313479419"><label>8</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Trachtman</surname><given-names>H</given-names></name><name><surname>Christen</surname><given-names>E</given-names></name><name><surname>Cnaan</surname><given-names>A</given-names></name><etal/></person-group>. <article-title>Urinary neutrophil gelatinase-associated lipocalcin in D+HUS: A novel marker of renal injury</article-title>. <source>Pediatr Nephrol</source> <year>2006</year>; <volume>21</volume>: <fpage>989</fpage>–<lpage>994</lpage>.</citation></ref>
<ref id="bibr9-0961203313479419"><label>9</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Supavekin</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Kucherlapati</surname><given-names>R</given-names></name><name><surname>Kaskel</surname><given-names>FJ</given-names></name><name><surname>Moore</surname><given-names>LC</given-names></name><name><surname>Devarajan</surname><given-names>P</given-names></name></person-group>. <article-title>Differential gene expression following early renal ischemia/reperfusion</article-title>. <source>Kidney Int</source> <year>2003</year>; <volume>63</volume>: <fpage>1714</fpage>–<lpage>1724</lpage>.</citation></ref>
<ref id="bibr10-0961203313479419"><label>10</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devarajan</surname><given-names>P</given-names></name><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Supavekin</surname><given-names>S</given-names></name><name><surname>Patterson</surname><given-names>LT</given-names></name><name><surname>Steven Potter</surname><given-names>S</given-names></name></person-group>. <article-title>Gene expression in early ischemic renal injury: Clues towards pathogenesis, biomarker discovery, and novel therapeutics</article-title>. <source>Mol Genet Metab</source> <year>2003</year>; <volume>80</volume>: <fpage>365</fpage>–<lpage>376</lpage>.</citation></ref>
<ref id="bibr11-0961203313479419"><label>11</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Devarajan</surname><given-names>P</given-names></name></person-group>. <article-title>Cellular and molecular derangements in acute tubular necrosis</article-title>. <source>Curr Opin Pediatr</source> <year>2005</year>; <volume>17</volume>: <fpage>193</fpage>–<lpage>199</lpage>.</citation></ref>
<ref id="bibr12-0961203313479419"><label>12</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nguyen</surname><given-names>MT</given-names></name><name><surname>Ross</surname><given-names>GF</given-names></name><name><surname>Dent</surname><given-names>CL</given-names></name><name><surname>Devarajan</surname><given-names>P</given-names></name></person-group>. <article-title>Early prediction of acute renal injury using urinary proteomics</article-title>. <source>Am J Nephrol</source> <year>2005</year>; <volume>25</volume>: <fpage>318</fpage>–<lpage>326</lpage>.</citation></ref>
<ref id="bibr13-0961203313479419"><label>13</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Kelly</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Kidney NGAL is a novel early marker of acute injury following transplantation</article-title>. <source>Pediatr Nephrol</source> <year>2006</year>; <volume>21</volume>: <fpage>856</fpage>–<lpage>863</lpage>.</citation></ref>
<ref id="bibr14-0961203313479419"><label>14</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>EM</given-names></name><name><surname>Cohen</surname><given-names>AS</given-names></name><name><surname>Fries</surname><given-names>JF</given-names></name><etal/></person-group>. <article-title>The 1982 revised criteria for the classification of systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>1982</year>; <volume>25</volume>: <fpage>1271</fpage>–<lpage>1277</lpage>.</citation></ref>
<ref id="bibr15-0961203313479419"><label>15</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gladman</surname><given-names>DD</given-names></name><name><surname>Ibanez</surname><given-names>D</given-names></name><name><surname>Urowitz</surname><given-names>MB</given-names></name></person-group>. <article-title>Systemic lupus erythematosus disease activity index 2000</article-title>. <source>J Rheumatol</source> <year>2002</year>; <volume>29</volume>: <fpage>288</fpage>–<lpage>291</lpage>.</citation></ref>
<ref id="bibr16-0961203313479419"><label>16</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Weening</surname><given-names>JJ</given-names></name><name><surname>D'Agati</surname><given-names>VD</given-names></name><name><surname>Schwartz</surname><given-names>MM</given-names></name><etal/></person-group>. <article-title>The classification of glomerulonephritis in systemic lupus erythematosus revisited</article-title>. <source>J Am Soc Nephrol</source> <year>2004</year>; <volume>15</volume>: <fpage>241</fpage>–<lpage>250</lpage>.</citation></ref>
<ref id="bibr17-0961203313479419"><label>17</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Illei</surname><given-names>GG</given-names></name><name><surname>Tackey</surname><given-names>E</given-names></name><name><surname>Lapteva</surname><given-names>L</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name></person-group>. <article-title>Biomarkers in systemic lupus erythematosus: II. Markers of disease activity</article-title>. <source>Arthritis Rheum</source> <year>2004</year>; <volume>50</volume>: <fpage>2048</fpage>–<lpage>2065</lpage>.</citation></ref>
<ref id="bibr18-0961203313479419"><label>18</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Illei</surname><given-names>GG</given-names></name><name><surname>Tackey</surname><given-names>E</given-names></name><name><surname>Lapteva</surname><given-names>L</given-names></name><name><surname>Lipsky</surname><given-names>PE</given-names></name></person-group>. <article-title>Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability</article-title>. <source>Arthritis Rheum</source> <year>2004</year>; <volume>50</volume>: <fpage>1709</fpage>–<lpage>1720</lpage>.</citation></ref>
<ref id="bibr19-0961203313479419"><label>19</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Merrill</surname><given-names>JT</given-names></name><name><surname>Buyon</surname><given-names>JP</given-names></name></person-group>. <article-title>The role of biomarkers in the assessment of lupus</article-title>. <source>Best Pract Res Clin Rheumatol</source> <year>2005</year>; <volume>19</volume>: <fpage>709</fpage>–<lpage>726</lpage>.</citation></ref>
<ref id="bibr20-0961203313479419"><label>20</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hahn</surname><given-names>BH</given-names></name></person-group>. <article-title>Antibodies to DNA</article-title>. <source>N Engl J Med</source> <year>1998</year>; <volume>338</volume>: <fpage>1359</fpage>–<lpage>1368</lpage>.</citation></ref>
<ref id="bibr21-0961203313479419"><label>21</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Blatt</surname><given-names>NB</given-names></name><name><surname>Glick</surname><given-names>GD</given-names></name></person-group>. <article-title>Anti-DNA autoantibodies and systemic lupus erythematosus</article-title>. <source>Pharmacol Ther</source> <year>1999</year>; <volume>83</volume>: <fpage>125</fpage>–<lpage>139</lpage>.</citation></ref>
<ref id="bibr22-0961203313479419"><label>22</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Waldman</surname><given-names>M</given-names></name><name><surname>Madaio</surname><given-names>MP</given-names></name></person-group>. <article-title>Pathogenic autoantibodies in lupus nephritis</article-title>. <source>Lupus</source> <year>2005</year>; <volume>14</volume>: <fpage>19</fpage>–<lpage>24</lpage>.</citation></ref>
<ref id="bibr23-0961203313479419"><label>23</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Qing</surname><given-names>X</given-names></name><name><surname>Zavadil</surname><given-names>J</given-names></name><name><surname>Crosby</surname><given-names>MB</given-names></name><etal/></person-group>. <article-title>Nephritogenic anti-DNA antibodies regulate gene expression in MRL/lpr mouse glomerular mesangial cells</article-title>. <source>Arthritis Rheum</source> <year>2006</year>; <volume>54</volume>: <fpage>2198</fpage>–<lpage>2210</lpage>.</citation></ref>
<ref id="bibr24-0961203313479419"><label>24</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>HI</given-names></name><name><surname>Mueller</surname><given-names>M</given-names></name><name><surname>Rutherford</surname><given-names>C</given-names></name><etal/></person-group>. <article-title>Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus</article-title>. <source>Arthritis Rheum</source> <year>2006</year>; <volume>54</volume>: <fpage>2577</fpage>–<lpage>2584</lpage>.</citation></ref>
<ref id="bibr25-0961203313479419"><label>25</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Wiers</surname><given-names>KM</given-names></name><name><surname>Klein-Gitelman</surname><given-names>MS</given-names></name><etal/></person-group>. <article-title>Neutrophil gelatinase-associated lipocalin as a biomarker of disease activity in pediatric lupus nephritis</article-title>. <source>Pediatr Nephrol</source> <year>2008</year>; <volume>23</volume>: <fpage>403</fpage>–<lpage>412</lpage>.</citation></ref>
<ref id="bibr26-0961203313479419"><label>26</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mishra</surname><given-names>J</given-names></name><name><surname>Dent</surname><given-names>C</given-names></name><name><surname>Tarabishi</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery</article-title>. <source>Lancet</source> <year>2005</year>; <volume>365</volume>: <fpage>1231</fpage>–<lpage>1238</lpage>.</citation></ref>
<ref id="bibr27-0961203313479419"><label>27</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hinze</surname><given-names>CH</given-names></name><name><surname>Suzuki</surname><given-names>M</given-names></name><name><surname>Klein-Gitelman</surname><given-names>M</given-names></name><etal/></person-group>. <article-title>Neutrophil gelatinase-associated lipocalin is a predictor of the course of global and renal childhood-onset systemic lupus erythematosus disease activity</article-title>. <source>Arthritis Rheum</source> <year>2009</year>; <volume>60</volume>: <fpage>2772</fpage>–<lpage>2781</lpage>.</citation></ref>
<ref id="bibr28-0961203313479419"><label>28</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rubinstein</surname><given-names>T</given-names></name><name><surname>Pitashny</surname><given-names>M</given-names></name><name><surname>Levine</surname><given-names>B</given-names></name><etal/></person-group>. <article-title>Urinary neutrophil gelatinase-associated lipocalin as a novel biomarker for disease activity in lupus nephritis</article-title>. <source>Rheumatology (Oxford)</source> <year>2010</year>; <volume>49</volume>: <fpage>960</fpage>–<lpage>971</lpage>.</citation></ref>
<ref id="bibr29-0961203313479419"><label>29</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kiani</surname><given-names>AN</given-names></name><name><surname>Wu</surname><given-names>T</given-names></name><name><surname>Fang</surname><given-names>H</given-names></name><etal/></person-group>. <article-title>Urinary vascular cell adhesion molecule, but not neutrophil gelatinase-associated lipocalin, is associated with lupus nephritis</article-title>. <source>J Rheumatol</source> <year>2012</year>; <volume>39</volume>: <fpage>1231</fpage>–<lpage>1237</lpage>.</citation></ref>
<ref id="bibr30-0961203313479419"><label>30</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Pitashny</surname><given-names>M</given-names></name><name><surname>Schwartz</surname><given-names>N</given-names></name><name><surname>Qing</surname><given-names>X</given-names></name><etal/></person-group>. <article-title>Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis</article-title>. <source>Arthritis Rheum</source> <year>2007</year>; <volume>56</volume>: <fpage>1894</fpage>–<lpage>1903</lpage>.</citation></ref>
<ref id="bibr31-0961203313479419"><label>31</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cross</surname><given-names>J</given-names></name><name><surname>Jayne</surname><given-names>D</given-names></name></person-group>. <article-title>Diagnosis and treatment of kidney disease</article-title>. <source>Best Pract Res Clin Rheumatol</source> <year>2005</year>; <volume>19</volume>: <fpage>785</fpage>–<lpage>798</lpage>.</citation></ref>
<ref id="bibr32-0961203313479419"><label>32</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Corwin</surname><given-names>HL</given-names></name><name><surname>Schwartz</surname><given-names>MM</given-names></name><name><surname>Lewis</surname><given-names>EJ</given-names></name></person-group>. <article-title>The importance of sample size in the interpretation of the renal biopsy</article-title>. <source>Am J Nephrol</source> <year>1988</year>; <volume>8</volume>: <fpage>85</fpage>–<lpage>89</lpage>.</citation></ref>
<ref id="bibr33-0961203313479419"><label>33</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname><given-names>A</given-names></name><name><surname>MacDermott</surname><given-names>EJ</given-names></name><name><surname>Lehman</surname><given-names>TJ</given-names></name></person-group>. <article-title>Pharmacotherapy of lupus nephritis in children: A recommended treatment approach</article-title>. <source>Drugs</source> <year>2006</year>; <volume>66</volume>: <fpage>1191</fpage>–<lpage>1207</lpage>.</citation></ref>
<ref id="bibr34-0961203313479419"><label>34</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ka</surname><given-names>SM</given-names></name><name><surname>Rifai</surname><given-names>A</given-names></name><name><surname>Chen</surname><given-names>JH</given-names></name><etal/></person-group>. <article-title>Glomerular crescent-related biomarkers in a murine model of chronic graft versus host disease</article-title>. <source>Nephrol Dial Transplant</source> <year>2006</year>; <volume>21</volume>: <fpage>288</fpage>–<lpage>298</lpage>.</citation></ref>
<ref id="bibr35-0961203313479419"><label>35</label><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Brunner</surname><given-names>HI</given-names></name><name><surname>Bennett</surname><given-names>MR</given-names></name><name><surname>Mina</surname><given-names>R</given-names></name><etal/></person-group>. <article-title>Association of noninvasively measured renal protein biomarkers with histologic features of lupus nephritis</article-title>. <source>Arthritis Rheum</source> <year>2012</year>; <volume>64</volume>: <fpage>2687</fpage>–<lpage>2697</lpage>.</citation></ref>
</ref-list>
</back>
</article>